In a recent review published in Obesity , researchers provide evidence-based suggestions for nutritional evaluation, treatment, and monitoring in patients taking anti-obesity medications (AOMs). Anti-obesity drugs have made tremendous progress in treating obesity, with an average weight decrease of ≥15%. However, introducing AOMs has resulted in limited dietary advice for patients undergoing these medications.
According to studies, energy consumption is likely to decrease with AOMs, with decreases of up to 345 kcal from baseline in individuals taking AOMs compared to placebo. Patient monitoring and counseling could reduce the possibility of dietary deficits. Additional study is required to close this knowledge gap.
In the present narrative review, researchers provide dietary advice for patients using new anti-obesity drugs based on PubMed data, including publication reference lists, emphasizing dietary, nutritional, weight reduction, obesity, low-calorie diets, malnutrition, and bariatric recommendations. Recent breakthroughs in AOMs have yielded encouraging outcomes in the treatment of obesity. Clinicians recommend AOMs as a supplement to lifestyle change for those with body mass index (BMI) values of ≥27 kg/m2 with one or more weight-associated concerns or individuals with BMI values of ≥30 kg/m2.
Since 2021, novel AOM drugs have developed with increased effectiveness and overall favorable safety profiles. These new-generation AOMs, such as semaglutide and tirzepatide.
